# Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy

> **NCT01827618** · EARLY_PHASE1 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 29 (actual)

## Conditions studied

- Invasive Bladder Cancer Stage II

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT01827618
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827618, "Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01827618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*